Results 271 to 280 of about 479,621 (361)
Symptom burden and palliative care in patients with hematologic malignancies: a single-center experience. [PDF]
Holopainen A +3 more
europepmc +1 more source
This study developed a hierarchical targeting nanoplatform, siTREM2@ETP‐PEOz‐OMVs, against triple‐negative breast cancer (TNBC) bone metastasis. It precisely delivers therapeutic siTREM2 to monocytes/macrophages within the metastatic niche. This intervention dually regulates cell fate: reprogramming immunosuppressive macrophages and inhibiting ...
Fanglu Chen +12 more
wiley +1 more source
Acute and Subacute Oral Toxicity Evaluation of <i>Baccaurea motleyana</i> Fruit Extract in Wistar Rats. [PDF]
Hasan MM +4 more
europepmc +1 more source
Lung cancer remains the leading cause of cancer‐related death. We investigated the role of the epigenetic regulator DMAP1 in NSCLC and found that its loss induces replication stress and DNA damage. This in turn activates type I IFN signaling via the cGAS–STING pathway and transcriptional ISG de‐repression, enhancing anti‐tumor immune responses ...
Kan Huang +10 more
wiley +1 more source
The impact of the graft-versus-leukemia effect on survival in acute lymphoblastic leukemia [PDF]
et al,, Uy, Geoffrey, Yeshurun, Moshe
core +1 more source
Genome-Wide Association Studies for 24 Hematological Traits in Production Pigs Before and After Weaning. [PDF]
Sun J +8 more
europepmc +1 more source
The PBTN targets GRP78 and, upon X‐ray irradiation, generates ONOO− to induce immunogenic cell death, thereby activating CD8+ T cells and establishing a systemic antitumor immune response. ABSTRACT Nitric oxide (NO) treated radioresistant tumors by relieving hypoxia and blocking DNA repair, but its nonselective toxicity has precluded therapeutic use ...
Wanze Zhang +10 more
wiley +1 more source
A mysterious foe in a case of pancytopenia with splenomegaly: Plasmodium vivax gametocytes in the bone marrow. [PDF]
Patel GR, Singh V.
europepmc +1 more source
AUTACE is a bifunctional nanoplatform that integrates tumor targeting, immune engagement, and on‐demand KRAS degradation. It targets KRAS/TP53 co‐mutant tumors via TP53‐specific TCRs, elicits antitumor CD8+ T‐cell responses through surface anti‐CD3 antibodies, and uses low‐intensity focused ultrasound (LIFU) to trigger controlled release of the KRAS ...
Luo Li +6 more
wiley +1 more source
This review examines emerging combination immunotherapy strategies tailored to distinct tumor microenvironments and highlights next‐generation biomarkers that guide response prediction and treatment personalization. It integrates lessons from unsuccessful trials, addresses toxicity challenges, and outlines approaches for early biomarker discovery and ...
Asmita Pandey +6 more
wiley +1 more source

